Expert Interview
Examining the Phase 3 TEMPO-2 Trial Evaluating Tavapadon as a Monotherapy for Parkinson's Disease
Ticker(s): ABBV, CEREInstitution: Montefiore Medical Center
- Director, Division of Movement Disorders and Assistant professor of Neurology at Albert Einstein College of Medicine
- Sees 220 patients with Parkinson's Disease yearly
- Clinical interest and contributor to journal articles and book chapters on a variety of neurologic topics
Describe your background and practice setting
Could you elaborate on the specific mechanisms through which tavapadon selectively activates D1/D5 dopamine receptors, and how this targeted action might contribute to its favorable safety profile compared to existing treatments?
Added By: ben_adminConsidering the results of the TEMPO-2 trial, what insights can we gain about tavapadon's potential to address the unmet needs of Parkinson's patients, particularly in terms of managing motor fluctuations and enhancing treatment efficacy over the long term?
Added By: ben_adminGiven the progressive nature of Parkinson's disease, how might tavapadon's once-daily dosing regimen contribute to treatment adherence and overall disease management, particularly in comparison to existing therapies with more frequent dosing requirements?
Could you discuss the safety profile of tavapadon as evidenced by the TEMPO-2 trial, particularly in terms of the nature and frequency of adverse events reported? How might these findings inform clinical decision-making and patient counseling regarding treatment initiation?
Added By: ben_adminLooking ahead, how do you envision tavapadon's role evolving in the landscape of Parkinson's disease treatment?
Added By: ben_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
